Touyun Biotech (01332) announced its performance for the six months ended June 30, 2024, with revenue of approximately 74.3 million Hong Kong dollars.
According to the Zhitong Finance APP, Touyun Biotech (01332) announced its performance for the six months ended June 30, 2024, with revenue of approximately 74.3 million Hong Kong dollars, a decrease of about 28.1% year-on-year; the company's shareholders' attributable loss was 48 million Hong Kong dollars, a decrease of 42.9% year-on-year. The basic loss per share is 1.71 Hong Kong cents.
The reduction in losses during the period was mainly due to effective cost control and a decrease in fair value losses on financial assets held for trading recognized in profit or loss at fair value.
